key: cord-0812874-v38kdzr8
authors: Hatton, Catherine F; Botting, Rachel A; Dueñas, Maria Emilia; Haq, Iram J; Verdon, Bernard; Thompson, Benjamin J; Spegarova, Jarmila Stremenova; Gothe, Florian; Stephenson, Emily; Gardner, Aaron I; Murphy, Sandra; Scott, Jonathan; Garnett, James P; Carrie, Sean; Powell, Jason; Khan, C M Anjam; Huang, Lei; Hussain, Rafiqul; Coxhead, Jonathan; Davey, Tracey; Simpson, A John; Haniffa, Muzlifah; Hambleton, Sophie; Brodlie, Malcolm; Ward, Chris; Trost, Matthias; Reynolds, Gary; Duncan, Christopher J A
title: Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2
date: 2021-09-09
journal: bioRxiv
DOI: 10.1101/2021.02.17.431591
sha: b54a4c0a1a968ed3579f232c870bfd26e864e4e0
doc_id: 812874
cord_uid: v38kdzr8

The nasal epithelium is a plausible entry point for SARS-CoV-2, a site of pathogenesis and transmission, and may initiate the host response to SARS-CoV-2. Antiviral interferon (IFN) responses are critical to outcome of SARS-CoV-2. Yet little is known about the interaction between SARS-CoV-2 and innate immunity in this tissue. Here we applied single-cell RNA sequencing and proteomics to a primary cell model of human nasal epithelium differentiated at air-liquid interface. SARS-CoV-2 demonstrated widespread tropism for nasal epithelial cell types. The host response was dominated by type I and III IFNs and interferon-stimulated gene products. This response was notably delayed in onset relative to viral gene expression and compared to other respiratory viruses. Nevertheless, once established, the paracrine IFN response began to impact on SARS-CoV-2 replication. When provided prior to infection, recombinant IFNβ or IFNλ1 induced an efficient antiviral state that potently restricted SARS-CoV-2 viral replication, preserving epithelial barrier integrity. These data suggest that the IFN-I/III response to SARS-CoV-2 initiates in the nasal airway and suggest nasal delivery of recombinant IFNs to be a potential chemoprophylactic strategy.

The nasal epithelium is believed to be a key entry point of SARS-CoV-2. Nasal epithelial tropism and 62 efficient viral shedding from the nasopharynx apparently contributes to the high transmissibility of 63 SARS-CoV-2 7 , as well as to pathologic features such as anosmia 8 . As an early viral target cell, nasal 64 epithelial cells may also set the tone for the systemic immune response, potentially influencing disease 

Collectively, these data suggested that the virus is capable of entering, and replicating in, all major 184 nasal cell types, but with quantitative differences in efficiency. 

Published ex vivo single-cell transcriptomic analyses report that nasal cell types exhibit the basal 208 expression of an innate antiviral gene signature, in the absence of viral infection, characterised by 209 several IFN-stimulated genes (ISGs) 10,11 . This signature correlated with ACE2 expression, suggesting 210 conditioned expression to reduce susceptibility. Based on these reports, we examined scRNA-seq data 211 to characterise the innate antiviral response of nasal cells to SARS-CoV-2 infection at 24 hpi. In 212 unexposed cells, ISG signature scores were generated using context-specific ISGs from a published IFN-treated nasal cell dataset 11 and compared using the Wilcoxon rank sum test. Gene set scores 214 greater than zero suggested expression levels higher than background gene expression, and was the 215 case for basal 1, secretory, goblet cells and ionocytes (Fig. 3A) . The basal ISG signature was highest in 216 secretory cells despite abundant expression of viral RNA in these cells upon exposure to SARS-CoV-2 217 ( Fig. 2A-B) , suggesting basal ISG expression may not be sufficient to protect against infection. Next we 218 distinguished cells in three experimental conditions: unexposed (mock-infected); SARS-CoV-2-219 exposed but uninfected (these 'bystander' cells would theoretically be exposed to IFNs and other 220 paracrine signals, but not infected); and SARS-CoV-2-infected (as defined by detectable expression of 221 SARS-CoV-2 transcripts). We undertook differential expression (DE) analysis between mock and 222 bystander or infected cells, labelling ISGs derived from the same list of context-specific ISGs ( 

Induction of IFNL1 and IFNB was low at 24 hpi, consistent with scRNA-seq findings, but increased 274 significantly by 48 and 72 hpi (Fig. 4A) . IFNA1 was not induced, as observed in our scRNA-seq data.

Compared to the timing of initiation of viral gene expression -which was detectable at 6 hpi and Table   328 S2). These data are consistent with our earlier findings and contrary to prior reports in cell lines or 329 human bronchial/tracheal epithelial cultures, where a robust endogenous IFN-I/III response to SARS-cluster (OAS1-3), the latter associated with genetic susceptibility to severe COVID-19 19 (Fig. 5C ).

Significantly downregulated pathways were also identified, including TRIF-dependent toll-like 333 receptor signalling, as well as RNA polymerase II transcription and endosomal transport (Table S3) . 

7A-B). This was accompanied by robust induction of antiviral ISG products (Fig. 7A) , and preservation 375 of barrier integrity (Fig. S10) . It is worth noting that the ISG expression induced in response to 376 recombinant IFN-I/III at 48 hpi was substantially greater than that induced by endogenous IFN-I/III 377 production (Fig. 7A) . Thus exogenous IFN-I/III was capable of inducing in the nasal epithelium an 

Interestingly, ISG induction was still observed in response to IFN treatment at 24 hpi, albeit at reduced 388 magnitude in the case of IFNb (Fig. 7C-D) . These data suggest that SARS-CoV-2 may impair, but does 

The main limitation of our data in this nasal epithelial culture system is that it did not account for 

In summary, we have shown that SARS-CoV-2 exhibits broad tropism for nasal epithelial cells, but with 530 preferential infection of ciliated and secretory cell types. Nasal cells mount a robust innate antiviral 531 response to SARS-CoV-2 dominated by paracrine IFN-I/III signalling, which is delayed in onset relative 532 to viral replication, but which is nevertheless capable of exerting partial control at later times post- 558   Table S4 .

A clinical isolate of SARS-CoV-2 (BetaCoV/England/2/2020) was obtained from Public Health England 562 (PHE). This was isolated from a patient in January 2020 and thus represents an early strain of SARS-563 CoV-2, not known to be affected by variants of concern. The initial stock was propagated once in vero probes. All other primer and probe information is described in Table S5 . Cycling conditions were as 644 follows: reverse transcription at 50°C for 15 min, followed by initial polymerase activation at 95°C for 645 10 min, then 40 cycles of denaturation at 95°C for 15 sec and annealing/extension at 60°C for 1 min.

The 2 -△△ Ct method was used to calculate the relative expression of genes. Each sample was run in 

(v/v) Triton X-100 (Sigma-Aldrich) before being blocked with a 1% (w/v) BSA solution in PBS with 0.5%

(v/v) Tween 20 (Sigma-Aldrich; PBST) for one hour at room temperature (RT). Membranes were 656 incubated with primary antibodies for 2 hours at RT. Antibodies used are listed in Table S6 .

Membranes were washed three times for 5 min in PBST before incubation with appropriate 658 fluorescence-conjugated secondary antibodies for 2 hours at RT. This process was repeated as part of 659 a sequential staining process where required. Membranes were washed three times for 5 min in PBST 660 before being incubated with DAPI (50 nM; Sigma-Aldrich) as a nuclear counterstain, and phalloidin,

DyLight 650 (1 unit/mL; ThermoFisher) where required, for 10 min. Membranes were then mounted 662 in MOWIOL mounting media (Sigma-Aldrich) and coverslips applied. Appropriate secondary only 663 controls were performed as required. Images were captured using a Nikon A1 confocal microscope Table S6 ). Blots were developed with Pierce ECL Western blotting substrate (Thermo statistical analysis purposes. Continuous data were normalised or log-transformed prior to analysis 728 using parametric significance tests, or if this was not possible, were analysed using nonparametric 729 significance tests. Differences between two groups were compared using an unpaired, two-tailed 730 Student's t-test (or Mann-Whitney test for TEM image analysis), whereas differences between more 731 than two groups used ANOVA, with Dunnett's post-test correction for multiple comparisons when 732 comparing to a single reference point (e.g. mock-infected or time zero) or with Sidak's post-test 733 correction for other multiple comparisons (e.g. between differently treated donors at the same time 734 point). In some cases, data were normalised to a reference point, where a one-sample t-test was used.

Unless stated otherwise, a two-tailed alpha of < 0.05 was the threshold for statistical significance.

Statistical analysis of proteomics and transcriptomics data sets is described in the relevant sections 

CFH is supported by a Medical Research Council studentship 762 (MR/NO13840/1) and MB by an MRC Clinician Scientist Fellowship (MR/M008797/1). MT and SH are 763 funded by Wellcome Investigator Awards

MED 765 is a Marie Sklodowska Curie Fellow within the European Union's Horizon 2020 research and innovation 766 programme under the Marie Sklodowska-Curie grant agreement No. 890296

The Lister Institute for Preventive Medicine

JPG, CW and BV were supported by the

Foundation (MRF Respiratory Diseases Research Award to JPG

AJS is a 771 National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article 772 are those of the author(s) and not necessarily those of the NIHR

The funders had no role in the study design, data collection and analysis

Conceived the study

Proteomics 780 data generation, analysis and interpretation: MED, SM, MT. Single-cell sequencing data generation, 781 analysis and interpretation

Approved the manuscript for submission

SH declares honoraria from CSL Behring and Takeda for teaching and consultancy. The remaining 788 authors declare no financial or non-financial competing interests

A Novel Coronavirus from Patients with Pneumonia in China

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 793 Blocked by a Clinically Proven Protease Inhibitor

Clinical features of patients infected with 2019 novel coronavirus in 796

Risk stratification of patients admitted to hospital with covid-19 798 using the ISARIC WHO Clinical Characterisation Protocol: development and validation 799 of the 4C Mortality Score

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary 801 Report

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): 803 a randomised, controlled, open-label, platform trial

Virology, transmission, and 806 pathogenesis of SARS-CoV-2

Elevated ACE-2 expression in the olfactory neuroepithelium: 808 implications for anosmia and upper respiratory SARS-CoV-2 entry and replication

Leveraging the antiviral type I interferon system as a first line of 811 defense against SARS-CoV-2 pathogenicity

SARS-CoV-2 entry factors are highly expressed in nasal epithelial 814 cells together with innate immune genes

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in 817

Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 820 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host 821 transcriptional profiles

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in 824 the Respiratory Tract

Characterization and Treatment of SARS-CoV-2 in Nasal and 826 Bronchial Human Airway Epithelia

Impaired local intrinsic immunity to SARS-CoV-2 infection in 829 severe COVID-19

Interferons and viruses induce a novel truncated ACE2 isoform 831 and not the full-length SARS-CoV-2 receptor

Genetic Lesions of Type I Interferon 834 Signalling in Human Antiviral Immunity

Inborn errors of type I IFN immunity in patients with life-threatening 837 COVID-19

Genetic mechanisms of critical illness in Covid-19

Autoantibodies against type I IFNs in patients with life-threatening 841 COVID-19

Type I Interferon Susceptibility Distinguishes SARS-CoV-2 843 from SARS-CoV

Inhibition of SARS-CoV-2 by type I and type III interferons

The type I interferon response in COVID-19: implications for 847 treatment

Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human 849 airway epithelial cells

Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and 852 susceptibility to therapies in primary human airway epithelium

Type I and Type III Interferons Restrict SARS-CoV-2 Infection of 855 Human Airway Epithelial Cultures

Imbalanced Host Response to SARS-CoV-2 Drives Development 857 of COVID-19

SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung 859

Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response

Real-time measurement of cellular bioenergetics in fully differentiated 862 human nasal epithelial cells grown at air-liquid-interface

A cellular census of human lungs identifies novel cell states in 865 health and in asthma

Novel dynamics of human mucociliary differentiation revealed by 868 single-cell RNA sequencing of nasal epithelial cultures

Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities

IFITM proteins promote SARS-CoV-2 infection and are targets for 873 virus inhibition in vitro

Metabolic reprogramming and epigenetic changes of vital organs in SARS-876

CoV-2-induced systemic toxicity

Host metabolic reprogramming in response to SARS-CoV-2 infection: A systems 879 biology approach

Single-cell longitudinal analysis of SARS-CoV-2 infection in human 882 airway epithelium identifies target cells, alterations in gene expression, and cell state 883 changes

Activation and evasion of type I interferon responses by SARS-CoV-2. Nat 885 Commun 11

Host Retromer Protein Sorting Nexin 2 Interacts with Human 887

Respiratory Syncytial Virus Structural Proteins and is Required for Efficient Viral 888 Production

Human 890 papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17

Severe type I interferonopathy and unrestrained interferon 893 signaling due to a homozygous germline mutation in STAT2

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) 896 for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-897 controlled, phase 2 trial

Type I interferons can be detected in respiratory swabs from SARS-900

Cov-2 infected patients

Dynamic innate immune response determines susceptibility to 903 SARS-CoV-2 infection and early replication kinetics

Upper airway gene expression reveals suppressed immune responses to 906 SARS-CoV-2 compared with other respiratory viruses

SARS-CoV-2 triggers an MDA-5-dependent interferon response 909 which is unable to control replication in lung epithelial cells

The RNA sensor MDA5 detects SARS-CoV-2 infection

MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung 914 Epithelial Cells

SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response 916 by Causing Depletion of Key Host Signaling Factors

Double-Membrane Vesicles as 919 Platforms for Viral Replication

SARS-CoV-2 uses a multipronged strategy to impede host protein 922 synthesis

SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit 924 translation

Structural basis for translational shutdown and immune evasion by 926 the Nsp1 protein of SARS-CoV-2

Translational 929 shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein

SARS-CoV-2 infection induces the dedifferentiation of multiciliated 932 cells and impairs mucociliary clearance

Untuned antiviral immunity in COVID-19 revealed by temporal type 935

Impaired type I interferon activity and inflammatory responses in 938 severe COVID-19 patients

Single-cell multi-omics analysis of the immune response in 940 COVID-19

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in 942 patients with autoantibodies against type I IFNs

Aging impairs both primary and secondary RIG-I signaling for 945 interferon induction in human monocytes

Pre-activated antiviral innate immunity in the upper airways controls 948 early SARS-CoV-2 infection in children

Direct Exposure to SARS-CoV-2 and Cigarette Smoke Increases 951 Infection Severity and Alters the Stem Cell-Derived Airway Repair Response

Analysis of plasmacytoid and myeloid dendritic cells in nasal 954 epithelium

SARS-CoV-2 induces human plasmacytoid pre-dendritic cell 956 diversification via UNC93B and IRAK4. bioRxiv

Plasmacytoid dendritic cells produce type I interferon and 959 reduce viral replication in airway epithelial cells after SARS-CoV-2 infection. bioRxiv

Natural mucosal barriers and COVID-19 in children

Impaired local intrinsic immunity to SARS-CoV-2 infection in 964 severe COVID-19. bioRxiv

Basal cells as stem cells of the mouse trachea and human airway 966 epithelium

Regulation of immune responses by the airway epithelial 969 cell landscape

Sensing of apoptotic cells through Axl causes lung basal cell 972 proliferation in inflammatory diseases

Allergic inflammatory memory in human respiratory 975 epithelial progenitor cells

Intrinsic Immunity Shapes Viral Resistance of Stem Cells

An experimental trial of recombinant human interferon alpha nasal 980 drops to prevent COVID-19 in medical staff in an epidemic area

STAT2 signaling restricts viral dissemination but drives severe 983 pneumonia in SARS-CoV-2 infected hamsters

Type I and III interferons disrupt lung epithelial repair during recovery 986 from viral infection

Type III interferons disrupt the lung epithelial barrier upon viral 988 recognition

CellBender remove-background: a deep 990 generative model for unsupervised removal of background noise from scRNA-seq 991 datasets. bioRxiv

Fast gene set enrichment analysis. bioRxiv

Robustness and applicability of transcription factor and pathway 995 analysis tools on single-cell RNA-seq data

Semi-quantitative Determination of Protein Expression using 998 Immunohistochemistry Staining and Analysis: An Integrated Protocol

The ProteomeXchange consortium in 2017: supporting the 1001 cultural change in proteomics public data deposition

The PRIDE database and related tools and resources in 2019: 1004 improving support for quantification data